🏢 公司NewsroomBSXDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 20:00:00(美东 08:00)·⟳ 抓取 20:00:41回填·⚡ 决策 10-26 20:01:28·1.3 天前
波士顿科学（BSX）公告将参加 Stifel 2026 医疗健康大会问答环节，无任何经营或财务增量信息
这是典型的投资者会议参会预告（conference participation notice），只有时间、地点、出席人和直播链接，没有任何需求、订单、业绩、指引、监管或资本结构层面的新增事实，对未来 1–10 个交易日的盈利或估值预期无方向性影响；问答本身在 2026-11-11 才举行，当前无 edge，也无任何二阶供应链映射可借题发挥。
📄 原文BSX↗ 原文
Boston Scientific to participate in Stifel's 2026 Healthcare Conference
MARLBOROUGH, Mass. , Oct. 26, 2026 / PRNewswire / -- Boston Scientific Corporation (NYSE: BSX) will participate in Stif…
不做 Boston Scientific Corporation（BSX.US）
无增量事实：仅为 2026-11-11 Stifel 医疗健康大会 30 分钟问答的参会与直播预告，无业绩、指引、订单、产品或监管信息，当前无任何可交易 edge；问答当日如有实质言论应作为独立新事件另行研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BSX 仅公告将出席 11 月 11 日 Stifel 医疗健康大会的例行问答环节，无新增事实或指引，属中性日历通知，不具备交易价值，回避。
🔎 新鲜度:最早出现 2026-10-26 · 扩散 low · price-in 风险 low ↗
主要风险
- 问答环节（11 月 11 日）现场若释放超预期言论可能引发波动，但那是未来独立事件，本公告本身不含任何可提前定位的信息。
先例如何影响了这次决策
对本次决策的影响:对最终结论无影响，AVOID 完全由事件本身缺乏增量事实决定。
方向:无可参考先例，也无必要：例行券商会议参会预告本身不含方向性催化。
涨幅量级:不适用——无交易主张，无需用先例校准幅度。
形态:未做先例检索；此类中性日历通知通常不产生系统性价格反应。
原文全文
展开原文 · 1,501 字
MARLBOROUGH, Mass.
,
Oct. 26, 2026
/
PRNewswire
/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2026 Healthcare Conference on Wednesday, November 11, 2026. Kenneth Stein, M.D., senior vice president and global chief medical officer, and Lance Bates, executive vice president and president, Interventional Cardiology & Vascular Therapies, will participate in a 30-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET.
A live webcast and replay of the session will be accessible at
https://investors.bostonscientific.com
. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at
www.bostonscientific.com
and follow us on
LinkedIn
.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com
Lauren Tengler
Investor Relations
+1 (508) 683-4479
BSXInvestorRelations@bsci.com
SOURCE Boston Scientific Corporation
,
Oct. 26, 2026
/
PRNewswire
/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2026 Healthcare Conference on Wednesday, November 11, 2026. Kenneth Stein, M.D., senior vice president and global chief medical officer, and Lance Bates, executive vice president and president, Interventional Cardiology & Vascular Therapies, will participate in a 30-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET.
A live webcast and replay of the session will be accessible at
https://investors.bostonscientific.com
. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at
www.bostonscientific.com
and follow us on
.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com
Lauren Tengler
Investor Relations
+1 (508) 683-4479
BSXInvestorRelations@bsci.com
SOURCE Boston Scientific Corporation
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
79c832f8f8· 2026-10-26 20:01 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前